Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 414-419 , June 2008

Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications

  • Eduardo Payá, MD

      Affiliations

    • Department of Cardiology, Hospital General Universitario, Alicante, Spain
    • ,
  • Francisco Marín, MD, PhD

      Affiliations

    • Department of Cardiology, Hospital General Universitario, Alicante, Spain
    • Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain
    • Corresponding Author InformationReprint requests: Francisco Marín, MD, PhD, Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Ctra Madrid-Cartagena, s/n, Murcia 30120, Spain.
    • ,
  • Josefa González, MD

      Affiliations

    • Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Juan Ramón Gimeno, MD, PhD

      Affiliations

    • Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Eloísa Feliu, MD, PhD

      Affiliations

    • Magnetic Resonance Unit, Inscanner, Hospital General Universitario, Alicante, Spain
    • ,
  • Antonio Romero, MD

      Affiliations

    • Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Francisco Ruiz-Espejo, MD

      Affiliations

    • Department of Clinical Analysis, Hospital Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Vanessa Roldán, MD, PhD

      Affiliations

    • Department of Hematology and Medical Oncology, Hospital Morales Meseguer, Murcia, Spain
    • ,
  • Vicente Climent, MD

      Affiliations

    • Department of Cardiology, Hospital General Universitario, Alicante, Spain
    • ,
  • Gonzalo de la Morena, MD, PhD

      Affiliations

    • Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Mariano Valdés, MD, PhD

      Affiliations

    • Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain

Received 6 October 2007 ,Revised 1 February 2008 ,Accepted 6 February 2008.

References 

  1. St John Sutton MG, Lie JT, Anderson KR, O'Brien PC, Frye RL. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J. 1980;44:433–443
  2. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260–2264
  3. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–1567
  4. Tsuruda T, Boerringter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Cir Res. 2002;91:1127–1134
  5. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997;77:130–132
  6. Fananapazir L, McAreavey D. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol. 1997;20:478–501
  7. Spirito P, Bellone P, Harris KM, Bernabó P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;324:1778–1785
  8. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303
  9. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987–2991
  10. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873–879
  11. Pohost GM, Hung L, Doyle M. Clinical use of cardiovascular magnetic resonance. Circulation. 2003;108:647–653
  12. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen E, Simonetti O, et al. Relation of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992–2002
  13. Moon JC. What is late gadolinium enhancement in hypertrophic cardiomyopathy?. Rev Esp Cardiol. 2007;60:1–4
  14. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Eur Heart J. 2003;24:2151–2155
  15. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–482
  16. Bogaert J, Goldstein M, Tannouri F, Golzarian J, Dymarkowski S. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. AJR Am J Roentgenol. 2003;180:981–985
  17. Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, Flamm SD. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J. 2002;29:176–180
  18. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156–2164
  19. Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22:155–161
  20. Debl K, Djavidani B, Buchner S, Lipke C, Nitz W, Feuerbach S, et al. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart. 2006;92:1447–1451
  21. Pujadas S, Carreras F, Arrastio X, Leta R, Vila M, Subirana MT, et al. Detection and quantification of myocardial fibrosis in hypertrophic cardiomyopathy by contrast-enhanced cardiovascular magnetic resonance. Rev Esp Cardiol. 2007;60:10–14
  22. Dumont C, Monserrat L, Soler R, Rodríguez E, Fernández X, Peteiro J, et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2007;60:15–23
  23. Soler R, Rodríguez E, Monserrat L, Mendez C, Martínez C. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. J Comput Assist Tomogr. 2006;30:412–420
  24. Hurwitz JL, Josephson ME. Sudden cardiac death in patients with chronic coronary heart disease. Circulation. 1992;85:143–149
  25. Matoh F, Satoh H, Shiraki K, Saitoh T, Urushida T, Katoh H, et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Cardiac Fail. 2007;13:372–379
  26. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, et al. Usefulness of N-terminal Pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:515–519
  27. Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J. 2005;150:1228–1232
  28. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109:984–989
  29. Pieroni M, Bellocci F, Sanna T, Verardo R, Ierardi C, Masseri A, et al. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Cardiac Fail. 2007;13:380–388
  30. Cochet A, Zeller M, Cottin Y, Robert-Valla C, Lalande A, L´Huilllier I, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur J Heart Fail. 2004;6:555–560
  31. Paelick BP, Vrints CJ, Bax JJ, Bosmans JM, De Hert SG, de Roos A, et al. Relation of B-type natriuretic peptide early after acute myocardial infarction to left ventricular diastolic function and extent of myocardial damage determined by magnetic resonance imaging. Am J Cardiol. 2006;97:1146–1150
  32. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94:453–461
  33. Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliú E, et al. Matrix metalloproteinases and tissue remodelling in hypertrophic cardiomyopathy. Am Heart J. In press.
  34. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb Haemost. 1995;73:561–567
  35. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007;99:31–35
  36. May HT, Muhlenstein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol. 2006;98:653–658
  37. Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS, Harjola VP. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J. 2006;27:3011–3017

PII: S1071-9164(08)00061-4

doi: 10.1016/j.cardfail.2008.02.006

Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 414-419 , June 2008

Article Tools

* Image Usage & Resolution